

Resource Summary Report

Generated by [RRID](#) on Aug 9, 2026

CD159a (NKG2A)-VioBright FITC, human

RRID:AB_2655382

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-105-646, RRID:AB_2655382

Antibody Information

URL: http://antibodyregistry.org/AB_2655382

Proper Citation: Miltenyi Biotec Cat# 130-105-646, RRID:AB_2655382

Target Antigen: CD159a (NKG2A)

Host Organism: human

Clonality: monoclonal

Comments: Discontinued: 12-2017; Target Distribution NK cells, T cells; target type CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity: Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-568. (RRID:AB_2726173).

Antibody Name: CD159a (NKG2A)-VioBright FITC, human

Description: This monoclonal targets CD159a (NKG2A)

Target Organism: non-human primate, human

Clone ID: REA110

Antibody ID: AB_2655382

Vendor: Miltenyi Biotec

Catalog Number: 130-105-646

Record Creation Time: 20250819T221629+0000

Record Last Update: 20250820T014050+0000

Ratings and Alerts

No rating or validation information has been found for CD159a (NKG2A)-VioBright FITC, human.

Warning: Discontinued: 2021

Discontinued: 12-2017; Target Distribution NK cells, T cells; target type CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-568. (RRID:AB_2726173).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Armani-Tourret M, et al. (2024) Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon- γ 2a. Cell, 187(5), 1238.

Nahi H, et al. (2022) Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma. Cell reports. Medicine, 3(2), 100508.

Cazzetta V, et al. (2021) NKG2A expression identifies a subset of human V α 2 T cells exerting the highest antitumor effector functions. Cell reports, 37(3), 109871.